Three Seasons Wealth LLC Invests $723,000 in Eli Lilly and Company (NYSE:LLY)

Three Seasons Wealth LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 937 shares of the company’s stock, valued at approximately $723,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Voya Financial Advisors Inc. increased its stake in Eli Lilly and Company by 12.9% during the fourth quarter. Voya Financial Advisors Inc. now owns 1,590 shares of the company’s stock worth $1,230,000 after purchasing an additional 182 shares during the period. Knightsbridge Asset Management LLC boosted its holdings in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after purchasing an additional 15 shares during the period. Nebula Research & Development LLC boosted its holdings in Eli Lilly and Company by 66.6% in the fourth quarter. Nebula Research & Development LLC now owns 4,097 shares of the company’s stock valued at $3,163,000 after purchasing an additional 1,638 shares during the period. Rothschild Capital Partners LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth $760,000. Finally, Topsail Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $564,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $861.11 on Friday. The firm has a market cap of $816.48 billion, a P/E ratio of 73.54, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The business’s 50-day moving average price is $827.14 and its 200 day moving average price is $818.81. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Morgan Stanley lowered their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a research note on Wednesday, April 9th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,017.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.